Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2013

Open Access 01-12-2013 | Research

Cathepsin B as a potential prognostic and therapeutic marker for human lung squamous cell carcinoma

Authors: Fengming Gong, Xingchen Peng, Can Luo, Guobo Shen, Chengjian Zhao, Liqun Zou, Longhao Li, Yaxiong Sang, Yuwei Zhao, Xia Zhao

Published in: Molecular Cancer | Issue 1/2013

Login to get access

Abstract

Background

The lung squamous cell carcinoma survival rate is very poor despite multimodal treatment. It is urgent to discover novel candidate biomarkers for prognostic assessment and therapeutic targets to lung squamous cell carcinoma (SCC).

Results

Herein a two-dimensional gel electrophoresis and ESI-Q-TOF MS/MS-based proteomic approach was used to identify differentially expressed proteins between lung SCC and adjacent normal tissues. 31 proteins with significant alteration were identified. These proteins were mainly involved in metabolism, calcium ion binding, signal transduction and so on. Cathepsin B (CTSB) was one of the most significantly altered proteins and was confirmed by western blotting. Immunohistochemistry showed the correlation between higher CTSB expression and lower survival rate. No statistically significant difference between CTSB-shRNA treated group and the controls was observed in tumor volume, tumor weight, proliferation and apoptosis. However, the CTSB-shRNA significantly inhibited tumor metastases and prolonged survival in LL/2 metastatic model. Moreover, CTSB, Shh and Ptch were up-regulated in patients with metastatic lung SCC, suggesting that hedgehog signaling might be activated in metastatic lung SCC which could affect the expression of CTSB that influence the invasive activity of lung SCC.

Conclusions

These data suggested that CTSB might serve as a prognostic and therapeutic marker for lung SCC.
Appendix
Available only for authorised users
Literature
1.
Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 2012, 62: 10-29. 10.3322/caac.20138CrossRefPubMed
2.
Boyle P, Ferlay J: Cancer incidence and mortality in Europe, 2004. Ann Oncol. 2005, 16: 481-488. 10.1093/annonc/mdi098CrossRefPubMed
3.
Kabuyama Y, Resing KA, Ahn NG: Applying proteomics to signaling networks. Curr Opin Genet Dev. 2004, 14: 492-498. 10.1016/j.gde.2004.07.001CrossRefPubMed
4.
Liu R, Li Z, Bai S, Zhang H, Tang M, Lei Y, Chen L, Liang S, Zhao YL, Wei Y, Huang C: Mechanism of cancer cell adaptation to metabolic stress: proteomics identification of a novel thyroid hormone-mediated gastric carcinogenic signaling pathway. Mol Cell Proteomics. 2009, 8: 70-85. 10.1074/mcp.M800195-MCP200CrossRefPubMed
5.
Poschmann G, Sitek B, Sipos B, Ulrich A, Wiese S, Stephan C, Warscheid B, Kloppel G, Vander Borght A, Ramaekers FC: Identification of proteomic differences between squamous cell carcinoma of the lung and bronchial epithelium. Mol Cell Proteomics. 2009, 8: 1105-1116. 10.1074/mcp.M800422-MCP200PubMedCentralCrossRefPubMed
6.
Yao H, Zhang Z, Xiao Z, Chen Y, Li C, Zhang P, Li M, Liu Y, Guan Y, Yu Y, Chen Z: Identification of metastasis associated proteins in human lung squamous carcinoma using two-dimensional difference gel electrophoresis and laser capture microdissection. Lung Cancer. 2009, 65: 41-48. 10.1016/j.lungcan.2008.10.024CrossRefPubMed
7.
Xu Y, Cao LQ, Jin LY, Chen ZC, Zeng GQ, Tang CE, Li GQ, Duan CJ, Peng F, Xiao ZQ, Li C: Quantitative proteomic study of human lung squamous carcinoma and normal bronchial epithelial acquired by laser capture microdissection. J Biomed Biotechnol. 2012, 2012: 510418-PubMed
8.
Tummalapalli P, Spomar D, Gondi CS, Olivero WC, Gujrati M, Dinh DH, Rao JS: RNAi-mediated abrogation of cathepsin B and MMP-9 gene expression in a malignant meningioma cell line leads to decreased tumor growth, invasion and angiogenesis. Int J Oncol. 2007, 31: 1039-1050.PubMedCentralPubMed
9.
Liotta LA, Kohn EC: The microenvironment of the tumour-host interface. Nature. 2001, 411: 375-379. 10.1038/35077241CrossRefPubMed
10.
Frlan R, Gobec S: Inhibitors of cathepsin B. Curr Med Chem. 2006, 13: 2309-2327. 10.2174/092986706777935122CrossRefPubMed
11.
Bengsch F, Buck A, Gunther SC, Seiz JR, Tacke M, Pfeifer D, von Elverfeldt D, Sevenich L, Hillebrand LE, Kern U: Cell type-dependent pathogenic functions of overexpressed human cathepsin B in murine breast cancer progression. Oncogene. 2013, 10.1038/onc.2013.395.
12.
Lim IT, Meroueh SO, Lee M, Heeg MJ, Mobashery S: Strategy in inhibition of cathepsin B, a target in tumor invasion and metastasis. J Am Chem Soc. 2004, 126: 10271-10277. 10.1021/ja0489240CrossRefPubMed
13.
Sinha AA, Gleason DF, Deleon OF, Wilson MJ, Sloane BF: Localization of a biotinylated cathepsin B oligonucleotide probe in human prostate including invasive cells and invasive edges by in situ hybridization. Anat Rec. 1993, 235: 233-240. 10.1002/ar.1092350207CrossRefPubMed
14.
Murnane MJ, Sheahan K, Ozdemirli M, Shuja S: Stage-specific increases in cathepsin B messenger RNA content in human colorectal carcinoma. Cancer Res. 1991, 51: 1137-1142.PubMed
15.
Rempel SA, Rosenblum ML, Mikkelsen T, Yan PS, Ellis KD, Golembieski WA, Sameni M, Rozhin J, Ziegler G, Sloane BF: Cathepsin B expression and localization in glioma progression and invasion. Cancer Res. 1994, 54: 6027-6031.PubMed
16.
Matarrese P, Ascione B, Ciarlo L, Vona R, Leonetti C, Scarsella M, Mileo AM, Catricala C, Paggi MG, Malorni W: Cathepsin B inhibition interferes with metastatic potential of human melanoma: an in vitro and in vivo study. Mol Cancer. 2010, 9: 207- 10.1186/1476-4598-9-207PubMedCentralCrossRefPubMed
17.
Sevenich L, Schurigt U, Sachse K, Gajda M, Werner F, Muller S, Vasiljeva O, Schwinde A, Klemm N, Deussing J: Synergistic antitumor effects of combined cathepsin B and cathepsin Z deficiencies on breast cancer progression and metastasis in mice. Proc Natl Acad Sci USA. 2010, 107: 2497-2502. 10.1073/pnas.0907240107PubMedCentralCrossRefPubMed
18.
Sevenich L, Werner F, Gajda M, Schurigt U, Sieber C, Muller S, Follo M, Peters C, Reinheckel T: Transgenic expression of human cathepsin B promotes progression and metastasis of polyoma-middle-T-induced breast cancer in mice. Oncogene. 2011, 30: 54-64. 10.1038/onc.2010.387CrossRefPubMed
19.
Gong F, Peng X, Zeng Z, Yu M, Zhao Y, Tong A: Proteomic analysis of cisplatin resistance in human ovarian cancer using 2-DE method. Mol Cell Biochem. 2011, 348: 141-147. 10.1007/s11010-010-0648-6CrossRefPubMed
20.
Rabilloud T, Adessi C, Giraudel A, Lunardi J: Improvement of the solubilization of proteins in two-dimensional electrophoresis with immobilized pH gradients. Electrophoresis. 1997, 18: 307-316. 10.1002/elps.1150180303.CrossRefPubMed
21.
Kreisberg JI, Malik SN, Prihoda TJ, Bedolla RG, Troyer DA, Kreisberg S, Ghosh PM: Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer. Cancer Res. 2004, 64: 5232-5236. 10.1158/0008-5472.CAN-04-0272CrossRefPubMed
22.
Anderson L, Seilhamer J: A comparison of selected mRNA and protein abundances in human liver. Electrophoresis. 1997, 18: 533-537. 10.1002/elps.1150180333CrossRefPubMed
23.
Chiang C, Litingtung Y, Lee E, Young KE, Corden JL, Westphal H, Beachy PA: Cyclopia and defective axial patterning in mice lacking sonic hedgehog gene function. Nature. 1996, 383: 407-413. 10.1038/383407a0CrossRefPubMed
24.
Yang L, Xie G, Fan Q, Xie J: Activation of the hedgehog-signaling pathway in human cancer and the clinical implications. Oncogene. 2010, 29: 469-481. 10.1038/onc.2009.392CrossRefPubMed
25.
Xie J: Implications of hedgehog signaling antagonists for cancer therapy. Acta Biochim Biophys Sin (Shanghai). 2008, 40: 670-680. 10.1111/j.1745-7270.2008.00431.xCrossRef
26.
Xie J: Hedgehog signaling pathway: development of antagonists for cancer therapy. Curr Oncol Rep. 2008, 10: 107-113. 10.1007/s11912-008-0018-7CrossRefPubMed
27.
Hwang JH, Lee SH, Lee KH, Lee KY, Kim H, Ryu JK, Yoon YB, Kim YT: Cathepsin B is a target of hedgehog signaling in pancreatic cancer. Cancer Lett. 2009, 273: 266-272. 10.1016/j.canlet.2008.08.028CrossRefPubMed
Metadata
Title
Cathepsin B as a potential prognostic and therapeutic marker for human lung squamous cell carcinoma
Authors
Fengming Gong
Xingchen Peng
Can Luo
Guobo Shen
Chengjian Zhao
Liqun Zou
Longhao Li
Yaxiong Sang
Yuwei Zhao
Xia Zhao
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2013
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-12-125

Other articles of this Issue 1/2013

Molecular Cancer 1/2013 Go to the issue

Research

Group X secreted phospholipase A2 induces lipid droplet formation and prolongs breast cancer cell survival

Research

6-Formylindolo (3,2-b)carbazole (FICZ) enhances retinoic acid (RA)-induced differentiation of HL-60 myeloblastic leukemia cells

Research

Combination therapy targeting integrins reduces glioblastoma tumor growth through antiangiogenic and direct antitumor activity and leads to activation of the pro-proliferative prolactin pathway

Research

Targeted therapy against EGFR and VEGFR using ZD6474 enhances the therapeutic potential of UV-B phototherapy in breast cancer cells

Short communication

POU1F1 is a novel fusion partner of NUP98 in acute myeloid leukemia with t(3;11)(p11;p15)

Research

miR-133b, a muscle-specific microRNA, is a novel prognostic marker that participates in the progression of human colorectal cancer via regulation of CXCR4 expression

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Highlights of the Day: Gynecologic cancer

Gynecologic Cancer Video

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Breast Cancer Video

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits